Viatris Inc.

NASDAQ:VTRS

Drug Manufacturers - Specialty & Generic

Healthcare
$20.28 -2.29%

-$0.36 today

Market cap
$23.25B
Beta
0.90
P/E (TTM)
-59.9
EPS (TTM)
-$0.26
Dividend yield
3.12%
52W Low $8.63High $17.53

Volume 13.21M

Average 10.58M

VTRS Stock-Based Compensation

Employee pay granted in shares or options; a non-cash expense that dilutes existing shareholders.

Viatris Inc.NASDAQ: VTRS

Stock-Based Compensation · Q2 FY2026 · quarter ended Jun 2026

Stock-based compensation grows, but more slowly than its trailing trend

Q2 FY2026 stock-based compensation of $38.7M rose 4.3% year over year, behind the +9.7% change in trailing-twelve-month stock-based compensation. Sequentially, it fell 19.7% from the prior quarter. Over 3 fiscal years it compounded at +15.1% a year.

Context

  • Stock-based compensation amounted to 1.2% of revenue in FY2025, up 0.3 pp from a year earlier.
  • Stock-based compensation increased in 2 of the last 3 fiscal years.

What to watch

Whether quarterly growth recovers from +4.3% toward the trailing-twelve-month pace of +9.7%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterJun 2026
$38.7M-19.7% QoQ
Last fiscal yearDec 2025
$177.7M+21.6% YoY
LTMJun 2026
$172.3M+9.7% YoY
Stock-Based Compensation past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+4.3%——
1 year+21.6%——
3-year CAGR+15.1%——
5-year CAGR——
10-year CAGR——

Stock-Based Compensation history

USD · from the cash flow

Latest · FY2025
177.7M USD
Year-over-year change
+21.6%
4-year CAGR
+12.4%

Stock-Based Compensation vs competitors

How VTRS compares with its peers on the latest reported figures

  • Peers report in different currencies, so stock-based compensation is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +9.7% is the 4th highest of 10, against a peer median of -10.2%.
  • Stock-based compensation amounts to 1.2% of revenue for VTRS, versus a peer median of 1.0%.
VTRS Competitors
Stock-Based Compensation for VTRS and competitors
Company Period LTM YoY 3-year CAGR% of revenue
VTRSViatris Inc.LTM Jun 2026$172.3M USD+9.7%+15.1%1.2%
TEVATeva Pharmaceutical Industries LimitedLTM Jun 2026$168M USD+24.4%+8.2%1.0%
BHCBausch Health Companies Inc.LTM Jun 2026$149M USD+12.9%+19.7%1.4%
RDYDr. Reddy's Laboratories LimitedLTM Sep 2026₹117M INR-72.7%—0.0%
ANIPANI Pharmaceuticals, Inc.LTM Mar 2026$29.06M USD-7.1%+37.5%3.1%
AMPHAmphastar Pharmaceuticals, Inc.LTM Mar 2026$28.16M USD+10.9%+15.2%3.9%
OGNOrganon & Co.LTM Sep 2026$28.04M USD-70.8%+0.9%0.5%
AMRXAmneal Pharmaceuticals, Inc.LTM Jun 2026$26.81M USD-10.2%+0.1%0.9%
ALKSAlkermes plcLTM Sep 2026$21.78M USD-76.6%+1.6%1.2%
HLNHaleon plcFY2025£0 GBP-100.0%—0.0%
Peer median (excluding VTRS) —-10.2%+8.2%1.0%

Competitors are the stored peer set for VTRS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(1.27B)2.08B54.7M(634.2M)(3.51B)
Depreciation & Amortization4.51B3.03B2.74B2.71B2.8B
Deferred Income Tax675.7M(25.9M)(387.1M)(767.6M)(476.5M)
Stock-Based Compensation111.2M116.4M180.7M146.1M177.7M
Change in Working Capital(1.8B)(922.6M)(711.3M)(318.6M)(2.5B)
Accounts Receivables59.3M(240.3M)78.6M300.1M334.6M
Inventory(427.6M)(259.5M)(613.3M)(723.4M)(106.4M)
Accounts Payables(70.4M)170.2M314.7M36M(168M)
Other Working Capital(1.37B)(593M)(491.3M)68.7M(2.56B)
Other Non-Cash Items797.4M(1.28B)922.1M1.17B5.84B
Operating Cash Flow3.02B3B2.8B2.3B2.32B
Capital Expenditures(509.4M)(489.4M)(474.5M)(326M)(378.8M)
Acquisitions (Net)277M0(667.7M)(350M)0
Purchases of Investments(30.2M)(30.2M)(26.3M)(26M)(23.9M)
Sales of Investments29.8M29.9M26.3M26M23.9M
Other Investing Activities115M1.96B280.6M2.48B(48.9M)
Investing Cash Flow(117.8M)1.47B(764.1M)1.8B(427.7M)
Debt Repayment(2.1B)(3.28B)(1.25B)(3.71B)100K
Common Stock Issued03.3M3.1M2.5M2.6M
Common Stock Repurchased(17.4M)0(250M)(250M)(500.5M)
Dividends Paid(399M)(581.6M)(575.6M)(574.8M)(561.2M)
Other Financing Activities(496.5M)(19.5M)(229.8M)205.6M(234.9M)
Financing Cash Flow(3.01B)(3.88B)(2.3B)(4.33B)(1.29B)
Effect of Forex Changes(30.9M)(38.9M)(2.5M)(30.7M)17.6M
Net Change in Cash(143.8M)556.3M(268.9M)(257.5M)611.9M
Free Cash Flow2.51B2.51B2.33B1.98B1.94B

Viatris Inc.

NASDAQ:VTRS

Intrinsic Alpha fair value

Locked

Current Price

$20.28

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.